An update from Telix Pharmaceuticals Ltd. ( (AU:TLX) ) is now available.
Telix Pharmaceuticals Limited announced a change in its reporting currency from Australian dollars to United States dollars, effective January 1, 2025. This shift aligns with the company’s revenue, costs, and cash flows predominantly generated in the U.S., potentially streamlining financial reporting and enhancing clarity for stakeholders.
More about Telix Pharmaceuticals Ltd.
Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Headquartered in Melbourne, Australia, Telix operates internationally in the United States, Canada, Europe, and Japan, with a portfolio targeting significant unmet medical needs in oncology.
YTD Price Performance: 32.39%
Average Trading Volume: 4,296
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $6.46B
Learn more about TLX stock on TipRanks’ Stock Analysis page.